Education
About Us
Working with TipRanks
Follow Us
Biophytis SA (DE:6XB3)
FRANKFURT:6XB3
6XB3 Stock Chart & Stats
€0.12
€0.00(0.00%)
At close: 4:00 PM EST
€0.12
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.04 - €0.37
Previous CloseN/A
Volume0.00
Average Volume (3M)241.00
Market Cap
€2.38M
Enterprise Value€7.88M
Total Cash (Recent Filing)€1.21M
Total Debt (Recent Filing)€7.77M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Feb 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding42,118,282
10 Day Avg. Volume1
30 Day Avg. Volume241
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage SpecializationSpecialization in age-related diseases and muscle-function therapeutics indicates a focused R&D strategy and domain expertise. A concentrated pipeline can create differentiated assets, streamline trial design and partner appeal, supporting durable value creation if clinical progress continues.
Improving Loss And Cash-burn TrendsMaterial narrowing of losses and reduced cash outflows in 2024 signals better cost control and operational discipline. Sustained improvements enhance runway and lower near-term financing pressure, increasing the company’s ability to reach clinical inflection points before further dilution.
Partial Debt Reduction Since 2022Measured reduction in debt improves balance-sheet flexibility and reduces leverage risk versus earlier peaks. Lower gross debt enhances negotiating leverage with partners and lenders and modestly reduces fixed financing costs, helping preserve cash for critical R&D activities.
Bears Say
No Revenue Over Multiple YearsAbsence of product revenue across multiple years means the company lacks operating cash generation and remains fully reliant on financing or partners. This structural revenue gap increases execution risk and constrains long-term sustainability until commercialization or licensing occurs.
Deeply Negative Shareholders' EquityDeep negative equity signals cumulative losses that impair solvency metrics and limit traditional financing options. Structural equity deficits can force dilutive recapitalizations or restrictive creditor terms, reducing strategic flexibility over the medium term.
Persistent Cash Burn And Funding DependenceConsistent negative operating and free cash flow create ongoing dependency on external financing. Even with 2024 improvement, the structural need for capital raises heightens dilution risk, constrains multi-year planning, and may delay or complicate advancement of pivotal clinical programs.
Biophytis SA News
6XB3 FAQ
What was Biophytis SA’s price range in the past 12 months?
Biophytis SA lowest stock price was €0.04 and its highest was €0.37 in the past 12 months.
What is Biophytis SA’s market cap?
Biophytis SA’s market cap is €2.38M.
When is Biophytis SA’s upcoming earnings report date?
Biophytis SA’s upcoming earnings report date is Feb 23, 2026 which is in 6 days.
How were Biophytis SA’s earnings last quarter?
Biophytis SA released its earnings results on Nov 04, 2025. The company reported -€0.18 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.18.
Is Biophytis SA overvalued?
According to Wall Street analysts Biophytis SA’s price is currently Overvalued.
Does Biophytis SA pay dividends?
Biophytis SA does not currently pay dividends.
What is Biophytis SA’s EPS estimate?
Biophytis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biophytis SA have?
Biophytis SA has 42,118,282 shares outstanding.
What happened to Biophytis SA’s price movement after its last earnings report?
Biophytis SA reported an EPS of -€0.18 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biophytis SA?
Currently, no hedge funds are holding shares in DE:6XB3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biophytis SA
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.